Description
Tradename:
Anafronil
Compound:
Each tablet contains:
Clomipramine hydrochloride 25 mg
Auxiliary components:
Lactose monohydrate, corn starch, anhydrous colloidal silicon dioxide, stearic acid, talc, magnesium stearate, glycerol 85%.
Properties:
An antidepressant from the group of tricyclic compounds. The effect of the drug is associated with stimulation of adrenergic and serotonergic mechanisms in the central nervous system due to inhibition of the reverse neuronal uptake of mediators. It has a greater effect on the uptake of serotonin; This appears to account for its effectiveness in the treatment of obsessive-compulsive disorders. The antidepressant effect occurs relatively quickly (in the first week of treatment).
Indications:
Depressive states of various etiologies (including endogenous, reactive, neurotic, organic, masked and involutional depression); depressive syndrome in schizophrenia and personality disorders; presenile and senile depression; depressive states with long-term pain syndrome and chronic somatic diseases; depressive disorders of a reactive, neurotic and psychopathic nature, including their somatic equivalents in children; obsessive-compulsive syndromes (phobia), panic attacks, chronic pain syndrome (chronic pain in cancer patients, migraine, rheumatic diseases, atypical pain in the face, postherpetic neuralgia, post-traumatic neuropathy, diabetic or other peripheral neuropathy), narcolepsy accompanied by cataplexy ; headache; migraine prevention.
Directions for use and dosage:
Orally for adults – 25-50 mg 2-3 times/day; for children, depending on age – 25-50 mg/day.
Contraindications:
Recent myocardial infarction, blockade of the myocardial conduction system, arrhythmias, mania, severe liver failure, angle-closure glaucoma, urinary retention, first trimester of pregnancy, lactation, hypersensitivity to clomipramine and other tricyclic antidepressants from the group of dibenzoazepine derivatives.
Precautionary measures:
Use with caution in patients with a reduced seizure threshold; for severe liver or kidney diseases; during treatment with steroid hormones; with pheochromocytoma and neuroblastoma due to the risk of developing a hypertensive crisis; with hyperthyroidism; diabetes mellitus (correction of the dosage regimen of hypoglycemic drugs is required).
Patients with suicidal tendencies in the initial period of treatment require constant medical supervision.
Side effects:
Dizziness, fatigue, tremor, headache, myoclonus, visual impairment; disturbances of taste, sensation of heat, mydriasis, disorientation, hallucinations. Nausea, dry mouth, constipation. Increased appetite, weight gain. Violations of libido and potency, galactorrhea, enlarged mammary glands.
Storage method:
At a temperature not higher than 30 degrees.
Package:
The cardboard box contains paper instructions and three blisters, each containing 10 tablets.
